http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2379066-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8a332e4cbb3f16e4a572f382d4cbdb4e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate | 2008-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e42dcc70900fb90cab7194bce8f83ffc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a1f7b95402317ff3bbd83e67e666c25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4db1f67f92ac0c4f10fd34247ed3d96b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab453036f5ee34bc4d832939a62f6cca |
| publicationDate | 2011-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2379066-A1 |
| titleOfInvention | Use of opioid antagonists for the preparation of a medicament in the treatment of retinal degenerative diseases |
| abstract | Retinal degenerative diseases affect the delicate layer of retina tissue that lines the inside back of the eye leading to gradual vision loss. The use of opioid anatgonists for the preparation of a medicament for the selective blocking of the body' s opioid receptors sites is a method of treating this human suffering by daily administration to the patient of from about 0,5 to about 10 mg of drugs such as naltrexone, naloxone or nalmefene. They act primarily by normalizing derangements in the human complement system that may occur in the disease etiology. Therapeutical approach for macular degeneration and retinitis pigmentosa is primarily intended. Oral, parenteral uses as well as topical applications may all be considered. They may be administered in one or divided doses daily for the best receptor blocking activity, preferably in the evening hours. Low Dose Naltrexone suitable for oral administration is most preferred regimen at about 4.5 mg / day. |
| priorityDate | 2008-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 76.